Home › Trial NCT05338619
A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy
- Trial IDNCT05338619
- StatusUnknown
- PhasePhase 2
- Study typeInterventional
- SponsorSung Yong Lee
- Enrollment77
- Start date2022-06-30
- ConditionsNon-small Cell Lung Cancer Stage III · EGFR Positive Non-small Cell Lung Cancer · Non-squamous Non-small-cell Lung Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.